Citi reiterates Buy/High Risk rating on HUTCHMED with target price of HK$40.10

Deep News10-14 12:20

Citi has issued a research report stating that HUTCHMED (00013) has seen an inflection point in its business operations driven by innovation, clinical progress, and sales recovery.

The bank has reiterated its Buy/High Risk rating on the stock with a target price of HK$40.1.

The report noted the scalability of the antibody-targeted conjugate drug (ATTC) transaction potential, as its design is modular across antibodies, customized linkers, and differentiated payloads.

The company expects new ATTC and other IND filings in the second half of 2026 through 2027.

The bank believes that with data disclosure or continued deal execution, the value of the ATTC platform will become more concrete; it also anticipates positive readout data from SAFFRON and SANOVO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189037702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-14 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189037702","market":"other","top_or_hot":-1,"title":"Citi reiterates Buy/High Risk rating on HUTCHMED with target price of HK$40.10","media":"Deep News","content":"<p>Citi has issued a research report stating that <b>HUTCHMED</b> (<b>00013</b>) has seen an inflection point in its business operations driven by innovation, clinical progress, and sales recovery.<br><br>The bank has reiterated its <b>Buy/High Risk</b> rating on the stock with a target price of HK$40.1.<br><br>The report noted the scalability of the antibody-targeted conjugate drug (ATTC) transaction potential, as its design is modular across antibodies, customized linkers, and differentiated payloads.<br><br>The company expects new ATTC and other IND filings in the second half of 2026 through 2027.<br><br>The bank believes that with data disclosure or continued deal execution, the value of the ATTC platform will become more concrete; it also anticipates positive readout data from SAFFRON and SANOVO.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citi reiterates Buy/High Risk rating on HUTCHMED with target price of HK$40.10</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCiti reiterates Buy/High Risk rating on HUTCHMED with target price of HK$40.10\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-10-14 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Citi has issued a research report stating that <b>HUTCHMED</b> (<b>00013</b>) has seen an inflection point in its business operations driven by innovation, clinical progress, and sales recovery.<br><br>The bank has reiterated its <b>Buy/High Risk</b> rating on the stock with a target price of HK$40.1.<br><br>The report noted the scalability of the antibody-targeted conjugate drug (ATTC) transaction potential, as its design is modular across antibodies, customized linkers, and differentiated payloads.<br><br>The company expects new ATTC and other IND filings in the second half of 2026 through 2027.<br><br>The bank believes that with data disclosure or continued deal execution, the value of the ATTC platform will become more concrete; it also anticipates positive readout data from SAFFRON and SANOVO.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1189037702","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189037702","pubTimestamp":1791951626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Citi has issued a research report stating that HUTCHMED (00013) has seen an inflection point in its business operations driven by innovation, clinical progress, and sales recovery.The bank has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","BK4504":"桥水持仓","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4588":"碎股","FTXO":"First Trust Nasdaq Bank ETF","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4207":"综合性银行","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK1191":"制药","BK1588":"回港中概股","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1144417596.USD":"UBS (LUX) GLOBAL QUALITY DIVIDEND EQUITY \"Q\" (USD) INC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","C":"花旗","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IYF":"金融指数ETF-iShares Dow Jones","BK4534":"瑞士信贷持仓","BK1587":"次新股","BK4585":"ETF&股票定投概念","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","EWH":"香港ETF-iShares MSCI","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4566":"资本集团","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","TFNS":"T. Rowe Price Financials ETF","00013":"和黄医药","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H"},"translate_title":"花旗重申和黄医药买入/高风险评级，目标价40.10港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"C":1,"IYF":1,"00013":1,"FTXO":1,"EWH":1,"TFNS":1},"content_text":"Citi has issued a research report stating that HUTCHMED (00013) has seen an inflection point in its business operations driven by innovation, clinical progress, and sales recovery.The bank has reiterated its Buy/High Risk rating on the stock with a target price of HK$40.1.The report noted the scalability of the antibody-targeted conjugate drug (ATTC) transaction potential, as its design is modular across antibodies, customized linkers, and differentiated payloads.The company expects new ATTC and other IND filings in the second half of 2026 through 2027.The bank believes that with data disclosure or continued deal execution, the value of the ATTC platform will become more concrete; it also anticipates positive readout data from SAFFRON and SANOVO.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189037702","isCrawlerRequest":true}